CASINVENT

Innovating cancer treatments by fighting resistant tumors with first-in-class inhibitors of casein kinase 1

INVESTMENT TEASER – SERIES A

Company Summary
Company
CasInvent Pharma, a.s.
Industry
Pharmaceuticals - oncology
Founded
2020
Management
CEO & CSO - Alexander Scheer
CFO & COO - Vojtech Helikar
Non-executive Director BD - Natalie Novac
Head of Biology - Tomasz Radaszkiewicz
Head of Chemistry - Kamil Paruch
IP Status
Patent granted, exlusively licenced
Indications
AML (Acute Myeloid Leukemia)
Melanoma, PDAC, Prostate cancer etc
Financing Sought
€ 10-12 M
Use of Funds
Reaching clinical proof-of-concept
New lead compounds for new indications
Planned Exit
2029

Profile

CasInvent Pharma *is Czech Republic leading drug discovery company developing a new class of proprietary small molecule compounds with in vivo activities in various cancers (liquid & solid). We are currently advancing the lead compound through late-stage preclinical development starting IND filing activities.*

Challenge:

Current targeted cancer therapies frequently face limitations due to resistance mechanisms, significantly reducing their effectiveness over time. Patients suffering from Acute Myeloid Leukemia (AML), melanoma, and pancreatic cancer (PDAC) often relapse and experience resistance to standard-of-care treatments.

Our Solution:

CasInvent Pharma has developed groundbreaking inhibitors targeting all three isoforms (α, δ, ε) of the Casein kinase 1 (CK1). Chosen from over 500 candidates, our lead compound shows exceptional in vivo efficacy in AML, overcoming resistance to conventional therapies. By simultaneously targeting CK1 α/δ/ε isoforms, our compounds bypass key cancer adaptation pathways, positioning this therapeutic strategy as highly promising for treating:

- *Venetoclax-resistant Acute Myeloid Leukemia (AML)*
- *BRAF inhibitor-resistant melanoma*
- *Gemcitabine-resistant Pancreatic Cancer (PDAC)*

IP

CasInvent Pharma holds exclusive licensing rights since 2020 to patented technology (WO2019185631), providing robust IP protection to support the company's clinical and commercial development.

Competition

CK1 inhibitors are being explored by pharma and biotech companies in oncology and CNS disorders (e.g., ALS, autism, and circadian rhythm). However, most current Phase II programs focus only on CK1α, often using targeted degraders. ***Our compounds are unique in inhibiting all three CK1 isoforms (α/δ/ε), which is synthetically challenging and market differentiating****. This pan-isoform approach is expected to deliver greater efficacy and a broader therapeutic window compared to CK1α-only degraders. Given recent high-profile publications and increasing biotech interest in CK1, pan isoform CK1 inhibitors like ours* ***hold significant blockbuster potential across oncology and CNS indications****.*

Current Status of Development

CasInvent Pharma *is currently in the preclinical stages of development. The IND filing is planned for 2026 after the completion of the advanced toxicology studies. Entry into the clinical phase Ia/b is planned for 2026/2027, with the exit of CasInvent Pharma envisaged for 2029.*

Value Proposition

CasInvent Pharma seeks € 10-12 M to reach the clinical stage of development in 2027 and to obtain clinical proof-of-concept in 2028.

Please contact us at invest@casinvent.com for more details about our science and fundraising